Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | POLR1A | O95602 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23775663 | 0.78 | ALOX15 (0.50) | LTA4HALDH1A1PKMPOLBKDM4E | |
| SCHEMBL14333873 | 0.78 | LTA4H (0.41) | LTA4HALDH1A1PKMPOLBKDM4E | |
| SCHEMBL13167818 | 0.78 | HRH3 (0.45) | LTA4HALDH1A1PKMHRH3SLC6A4 | |
| SCHEMBL102899 | 0.78 | SLC18A3 (0.43) | LTA4HALDH1A1PKMPOLBKDM4E | |
| SCHEMBL9807476 | 0.78 | LTA4H (0.41) | LTA4HALDH1A1PKMPOLBKDM4E | |
| Hydrochloric Acid SCHEMBL9560035 | 0.77 | LTA4H (0.40) | LTA4HALDH1A1PKMPOLBKDM4E | |
| SCHEMBL6063742 | 0.77 | ALDH1A1 (0.42) | LTA4HALDH1A1PKMPOLBKDM4E | |
| SCHEMBL11411310 | 0.77 | ALDH1A1 (0.38) | LTA4HALDH1A1PKMPOLBKDM4E | |
| SCHEMBL27756873 | 0.75 | GNAO1 (0.47) | LTA4H | |
| SCHEMBL25698059 | 0.75 | LTA4H (0.37) | LTA4HALDH1A1PKMPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666863-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2010-02-23 | — | — | US | claimed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | claimed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | claimed |
| US-7666863-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2009-11-12 | — | — | US | disclosed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | disclosed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1746888-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005112640-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | LTA4H 1456/4885ALDH1A1 189/4885PKM 2758/4885 |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | LTA4H 1456/4885ALDH1A1 189/4885PKM 2758/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | LTA4H 1456/4885ALDH1A1 189/4885PKM 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.